Business description: Ipsen

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:

- oncology (69.2%);

- neuroscience (20.3%);

- rare diseases (10.5%).

At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.

Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).

Number of employees: 5,535

Sales by Activity: Ipsen

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

Specialty Care

2.75B 3.16B 3.31B 3.57B 3.93B

Consumer Healthcare

250M - - - -

Geographical breakdown of sales: Ipsen

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

United States

- - - - 1.21B

Europe

- 1.24B 1.26B 1.34B 1.17B

Rest of World

- 756M 829M 897M 924M

France

314M - - - 293M

North America

916M 1.03B 1.04B 1.17B 80.3M

Eastern Europe

261M - - - -

Other Rest of The World

260M - - - -

Asia

252M - - - -

Others Europe

295M - - - -

U.K.

116M - - - -

Germany

199M - - - -

Italy

130M - - - -

Spain

125M - - - -

Executive Committee: Ipsen

Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 59 22/09/2023
Chief Tech/Sci/R&D Officer 52 05/05/2023

Composition of the Board of Directors: Ipsen

Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Director/Board Member 57 01/06/2020
Director/Board Member 68 27/05/2015
Director/Board Member 69 07/06/2017
Director/Board Member 60 01/05/2018
Director/Board Member 59 01/07/2020
Director/Board Member 47 06/11/2020
Director/Board Member - -

Shareholders: Ipsen

NameStocks%Valuation
26.03 %
21,816,679 26.03 % 3 838 M €
Estate of Henri Beaufour
26.03 %
21,816,679 26.03 % 3 838 M €
4.989 %
4,181,583 4.989 % 736 M €
1.703 %
1,427,498 1.703 % 251 M €
Arca Fondi SGR SpA
0.2123 %
177,932 0.2123 % 31 M €
NameStocks%Valuation
Ativo Capital Management LLC
0.0115 %
38,700 0.0115 % 2 M €

Holdings: Ipsen

NameStocks%Valuation
1,427,4981.7% 251 M $
4,007,9698% 49 M $

Company details: Ipsen

Ipsen SA

70 rue Balard

75015, Paris

+33 1 58 33 50 00

http://www.ipsen.com
address Ipsen(IPN)

Group companies: Ipsen

NameCategory and Sector
Socapharma SAS
Pharmaceuticals: Major
Pharmaceuticals: Major

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-3.23%+27.24%+50.61% 14.61B
-0.42%-6.29%+29.66%+126.36% 1,204B
+1.30%-5.15%+33.47%+80.80% 643B
+1.35%-2.14%+25.84%+108.76% 501B
-0.60%-2.39%+27.92%+67.00% 378B
+0.38%-9.03%+41.54%+30.91% 327B
+0.41%-4.81%+24.99%+51.91% 285B
+0.81%-3.72%-1.35%+30.72% 270B
+0.01%-5.78%+30.56%+65.36% 237B
+0.15%-0.01%+34.46%+121.13% 207B
Average +0.26%-4.24%+27.43%+73.36% 407B
Weighted average by Cap. +0.28%-4.70%+28.48%+88.11%
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
161.60EUR
Average target price
162.23EUR
Spread / Average Target
+0.39%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen